Among pharmacologic options, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained particular interest over recent years (33, 34)
P-LLY Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners
The Four Peptides That Power KLOW 1
Studies of glucose metabolism have shown that low doses of DPP4i that reduce DPP-4 activity within the gut, but not meaningfully in the systemic circulation, are sufficient to improve glucose tolerance (19, 20)
Safety and effectiveness of longer-term phentermine use: Clinical outcomes from an electronic health record cohort, Obesity (2019) Qsymia, DailyMed (2024) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial, The Lancet (2011) Long-term drug treatment for obesity: A systematic and clinical review, JAMA (2014) Lillys Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs
Many patients stay on a plan for 36 months, followed by ongoing review